EXAS - EXACT SCIENCES CORP
IEX Last Trade
57.6
-0.120 -0.208%
Share volume: 30,169
Last Updated: Fri 27 Dec 2024 08:30:08 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$57.72
-0.12
-0.21%
Fundamental analysis
8%
Profitability
0%
Dept financing
35%
Liquidity
38%
Performance
1%
Performance
5 Days
-2.46%
1 Month
-6.82%
3 Months
-12.86%
6 Months
29.20%
1 Year
-24.05%
2 Year
16.88%
Key data
Stock price
$57.60
DAY RANGE
$57.10 - $57.97
52 WEEK RANGE
$41.92 - $79.62
52 WEEK CHANGE
-$22.30
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: Kevin T. Conroy
Region: US
Website: exactsciences.com
Employees: 6,400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: exactsciences.com
Employees: 6,400
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Exact Sciences Corporation provides cancer screening and diagnostic test products. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers.
Recent news